Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Innovations 2022 in the field of hemostasis-thrombosis

Journal article

Bailly S. et al, (2023), Louvain Medical, 142, 101 - 108

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.

Journal article

Pecquet C. et al, (2023), Blood, 141, 917 - 929

Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.

Journal article

Lecomte S. et al, (2023), Blood, 141, 490 - 502

Editorial: Recent advances in molecular and structural endocrinology.

Journal article

De Meyts P. and Constantinescu SN., (2023), Frontiers in endocrinology, 14

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?

Journal article

Havelange V. and Constantinescu SN., (2023), American Journal of Hematology

The 2 faces of ERK2 in MPNs.

Journal article

Havelange V. and Constantinescu SN., (2022), Blood, 140, 298 - 300

Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

Journal article

Brodin P. et al, (2022), Nature medicine, 28, 879 - 882

JAK inhibitors and COVID-19.

Journal article

Levy G. et al, (2022), Journal for immunotherapy of cancer, 10

2021 Innovation in hematology

Journal article

Vekemans MC. et al, (2022), Louvain Medical, 141, 85 - 102

Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Journal article

Constantinescu SN. and Pecquet C., (2021), Blood, 138, 2301 - 2302

MPL S505C enhances driver mutations at W515 in essential thrombocythemia.

Journal article

Varghese LN. et al, (2021), Blood cancer journal, 11

Load More